KMT2A and acute myeloid leukemia: Indeed, while the incidence of pediatric AML was estimated to be about 8.1 per million person-years [47], the RUNX1-RUNX1T1, PML-RARα, and KMT2A-MLLT3 PFGs present in about 12–14%, 6–10% [3], and 6–7% [17] of total AML cases, respectively.